Dyne Therapeutics (NASDAQ:DYN) Posts Earnings Results, Beats Expectations By $0.02 EPS

Key Points

• Dyne Therapeutics reported an earnings per share (EPS) of ($0.97), beating analyst expectations of ($0.99) by $0.02.
• CEO John Cox acquired 100,000 shares of Dyne Therapeutics stock at an average price of $9.11, increasing his ownership significantly.
• Analysts have generally issued positive ratings for Dyne Therapeutics, with an average target price of $40.63 and most ratings categorized as "Moderate Buy."

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) released its earnings results on Monday. The company reported ($0.97) EPS for the quarter, topping analysts' consensus estimates of ($0.99) by $0.02, Zacks reports.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock traded down $0.64 on Monday, reaching $9.31. 2,225,435 shares of the company's stock were exchanged, compared to its average volume of 2,564,391. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $47.45. The firm's 50-day moving average is $10.93 and its two-hundred day moving average is $11.63. The company has a market capitalization of $1.06 billion, a P/E ratio of -2.59 and a beta of 1.08.

Insider Buying and Selling at Dyne Therapeutics

In related news, CEO John Cox purchased 100,000 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was acquired at an average cost of $9.11 per share, with a total value of $911,000.00. Following the transaction, the chief executive officer owned 242,179 shares of the company's stock, valued at $2,206,250.69. This represents a 70.33% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.77% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its holdings in Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company's stock worth $10,407,000 after acquiring an additional 366,183 shares during the last quarter. AQR Capital Management LLC bought a new stake in Dyne Therapeutics in the 1st quarter worth approximately $246,000. Caxton Associates LLP bought a new stake in Dyne Therapeutics in the first quarter valued at approximately $157,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company's stock valued at $597,000 after buying an additional 2,886 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. HC Wainwright lowered their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Sanford C. Bernstein assumed coverage on shares of Dyne Therapeutics in a research report on Tuesday, June 24th. They issued a "market perform" rating and a $13.00 target price for the company. Raymond James Financial began coverage on shares of Dyne Therapeutics in a research report on Wednesday, June 11th. They issued an "outperform" rating and a $37.00 target price for the company. Robert W. Baird reduced their price objective on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a research note on Wednesday, June 18th. Finally, Jones Trading assumed coverage on shares of Dyne Therapeutics in a research note on Thursday, June 26th. They set a "buy" rating and a $30.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has an average rating of "Moderate Buy" and an average target price of $40.63.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.